10-Q: Aspira Women's Health Reports First Quarter 2025 Results, Navigates Financial Challenges

Aspira Women's Health reports a slight revenue increase in Q1 2025 but faces going concern doubts amid ongoing losses and a Nasdaq delisting.

Summary

• Aspira Women's Health reported product revenue of $2.279 million for the three months ended March 31, 2025, a 6% increase compared to $2.153 million for the same period in 2024.
• The company's net loss for the quarter was $1.853 million, a significant improvement from the $4.629 million loss in Q1 2024.
• The number of OvaSuite tests performed decreased by 2.6% to 5,679 in Q1 2025, compared to 5,829 in Q1 2024.
• The average unit price (AUP) for OvaSuite tests increased to $401 in Q1 2025, up from $369 in Q1 2024.
• Cost of product revenue decreased by 23% to $719,000 in Q1 2025, compared to $939,000 in Q1 2024.
• The company's gross profit margin increased to 68.5% in Q1 2025, compared to 56.4% in Q1 2024.
• Research and development expenses increased by 7% to $973,000 in Q1 2025.
• Sales and marketing expenses decreased by 43% to $1.086 million in Q1 2025.
• General and administrative expenses decreased by 12% to $2.741 million in Q1 2025.
• The company is facing substantial doubt about its ability to continue as a going concern within one year after the date these consolidated interim financial statements are filed.
• Aspira's common stock was delisted from Nasdaq and began trading on the OTC Markets Group under the symbol AWHL on April 17, 2025.
• The company successfully applied for trading on the OTC QB Venture Market effective May 7, 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's some revenue growth and improved loss figures, the going concern warning and Nasdaq delisting weigh heavily on the overall sentiment. The potential for future capital raises adds further uncertainty.

Positives

• The company realized a 94% increase in sales per full-time equivalent salesperson compared to Q1 2024.
• The company received $1.5 million from ARPA-H in Q1 2025.
• Gross profit margin increased to 68.5% in Q1 2025, up from 56.4% in Q1 2024.
• Sales and marketing expenses were reduced by 43% in Q1 2025.

Negatives

• The company is facing substantial doubt about its ability to continue as a going concern within one year.
• Aspira's common stock was delisted from Nasdaq.
• The number of OvaSuite tests performed decreased by 2.6% to 5,679 in Q1 2025, compared to 5,829 in Q1 2024.
• The company has an accumulated deficit of approximately $533.25 million as of March 31, 2025.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company's stock is now traded on the OTC QB Venture Market, which may result in lower liquidity and trading volumes.
• The company's future liquidity and capital requirements will depend on various factors, including the rate of product adoption, reimbursement by payers, and the potential need to add study sites.
• The company's ability to use its net operating loss carryforwards is restricted due to ownership change limitations.

Future Outlook

The company expects to continue to incur a net loss and negative cash flows from operations for the remainder of 2025 and is exploring various options to improve its liquidity position, including raising capital, securing debt, and reducing expenses.

Industry Context

The company operates in the diagnostic testing market, which is characterized by rapid technological advancements and increasing demand for non-invasive diagnostic solutions. The company's focus on gynecologic diseases, particularly ovarian cancer and endometriosis, aligns with the growing awareness and unmet needs in women's health.

Comparison to Industry Standards

• It is difficult to compare Aspira's results directly to industry standards due to its specific focus on gynecologic diagnostics and its current financial challenges.
• Comparable companies in the diagnostic testing space, such as Myriad Genetics or Exact Sciences, typically have higher revenue and market capitalization, but they also operate in broader markets.
• Aspira's gross profit margin of 68.5% is competitive with industry averages for diagnostic testing companies.
• However, its negative net income and going concern doubts are significant concerns compared to more established players in the industry.

Management Changes

Legal Proceedings

• From time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations.
• The Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company's financial position or results of operations.

Related Party Transactions

• On December 1, 2023, the Company entered into a consulting agreement with Biodesix, Inc. (the Biodesix Agreement) to assist with our miRNA product pipeline, Jack Schuler, a beneficial owner of more than 5 % of the Company's stock, is also a beneficial owner of more than 10 % of the stock of Biodesix, Inc.
• On March 5, 2025, the Company entered into the March 2025 Private Placement with the Purchasers for the issuance and sale of Convertible Notes, Jack Schuler purchased $200,000 of the Convertible Notes.
• The Purchasers are entitled to three representatives on the Company's board of directors.

Stakeholder Impact

• Shareholders are impacted by the Nasdaq delisting and the potential for dilution from future capital raises.
• Employees face uncertainty due to the company's going concern warning and potential cost-cutting measures.
• Customers may be affected by changes in the company's product offerings or service levels.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company intends to use the net proceeds received from the Purchase Agreement for ongoing commercial activities as well as general corporate purposes and working capital.
• The company plans to continue to expand access to our tests among Medicaid patients as part of our corporate mission to make the best care available to all women, and we plan to advocate for legislation and the adoption of our technology in professional society guidelines to provide broad access to our products and services.

Key Dates

Keywords

Aspira Women's Health, Ova1Plus, OvaWatch, Financial Results, Q1 2025, Diagnostic Tests, ARPA-H, Nasdaq Delisting, OTC QB, Going Concern